Pharmacokinetic evaluation of liposomal nanoparticle-encapsulated nucleic acid drug: A combined study of dynamic PET imaging and LC/MS/MS analysis

• Published in: Journal of controlled release 2019-01, Vol.294, p.185-194
• Main Authors: Mukai, Hidefumi, Hatanaka, Kentaro, Yagi, Nobuhiro, Warashina, Shota, Zouda, Maki, Takahashi, Maiko, Narushima, Kazuya, Yabuuchi, Hayato, Iwano, Junko, Kuboyama, Takeshi, Enokizono, Junichi, Wada, Yasuhiro, Watanabe, Yasuyoshi
• Format: Article
• Language: English
• Subjects: 64Cu; Animals; Antisense drugs; Cell Line, Tumor; Chromatography, Liquid; Female; Humans; Liposomes; Liquid chromatography-tandem mass spectrometry; Mice; Nanoparticles - administration & dosage; Neoplasms - diagnostic imaging; Neoplasms - metabolism; Oligonucleotides - administration & dosage; Oligonucleotides - pharmacokinetics; Pharmacokinetics; Positron emission tomography; Tandem Mass Spectrometry; Tissue Distribution
• ISSN: 0168-3659; 1873-4995
• DOI: 10.1016/j.jconrel.2018.12.006

In vivo biodistribution analyses, especially in tumors, of nucleic acids delivered with nanoparticles are important to develop drug delivery technologies for medical use. We previously developed wrapsome® (WS), an ~100 nm liposomal nanoparticle that can encapsulate siRNA, and reported that WS accumulates in tumors in vivo and inhibits their growth by an enhanced permeability and retention effect. In the present study, we evaluated the pharmacokinetics of nucleic acid-containing nanoparticles by combining dynamic positron emission tomography (PET) imaging and liquid chromatography-tandem mass spectrometry (LC/MS/MS) analysis. An 18-mer phosphorothioate oligodeoxynucleotide (ODN), trabedersen, was used as a model drug and was encapsulated in WS. Dynamic PET imaging and time-activity curve analysis of WS-encapsulated 64Cu-labeled ODNs administered to mice with MIA PaCa-2 subcutaneous xenograft tumors showed tumor accumulation (~3% injected dose per gram (%ID/g)) and liver accumulation (~30 %ID/g) at 24 h. Under these conditions, LC/MS/MS analysis showed that the level of intact ODNs was 1.62 %ID/g in the tumor and 1.70 %ID/g in the liver. From these pharmacokinetic data, the intact/accumulated ODN ratios were calculated using the following equation: intact/accumulated ODN ratio (%) = %ID/g LC/MS/MS, tissue, mean/%ID/g PET, tissue, mean × 100. Interestingly, the ratios for the tumor and kidney were maintained at 20–50% over 48 h after administration of the WS-encapsulated form. In contrast, the ratio for the liver rapidly decreased at 24 h, showing the same pattern as that for naked ODN. These different patterns indicate that WS effectively protected the ODN in the tumor and kidney, but protected it less efficiently in the liver. A combined approach of dynamic PET imaging and LC/MS/MS analysis will assist the development of nanoparticle-encapsulated nucleic acid drugs, such as those using WSs, to determine their detailed pharmacokinetics. [Display omitted] •Dynamic PET and LC/MS/MS have complementary advantages for pharmacokinetic analysis.•Their combination provides the detailed pharmacokinetics of nucleic acid drugs.•Intact/accumulated ratios provide a stability index of nucleic acid drugs in vivo.•Wrapsome® (WS) efficiently delivers the intact nucleic acid drugs to tumors in mice.•WS protects nucleic acid drugs in the blood/tumor/kidneys, but not in the liver.